Open Access

Icotinib and pemetrexed in treatment of lung adenocarcinoma and the effects on prognostic survival rate of patients

  • Authors:
    • Xueheng Zhou
    • Defeng Hua
    • Chengpeng Gao
    • Yixiang Zhang
    • Lijie Qiu
    • Leqiang Wang
  • View Affiliations

  • Published online on: August 16, 2019     https://doi.org/10.3892/ol.2019.10763
  • Pages: 4153-4159
  • Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Efficacy comparison of icotinib and pemetrexed in the treatment of lung adenocarcinoma and the effects on the prognostic survival rate of patients were investigated. A retrospective analysis was performed in 132 lung adenocarcinoma patients who were treated in the Affiliated Hospital of Weifang Medical University from July 2010 to July 2015. Among them, 69 patients were treated with icotinib (icotinib group), and 63 patients were treated with pemetrexed (pemetrexed group). In the icotinib group, 125 mg icotinib was orally administered continuously, 3 times a day, until progressive disease or intolerable adverse reactions occurred. In the pemetrexed group, 500 mg/m2 pemetrexed was intravenously dripped for a total of 4 cycles, 21 days for 1 cycle, until progressive disease or intolerable adverse reactions occurred. The efficacy, toxic and side effects, and survival rate of the two groups were evaluated. There was a statistically significant difference in toxic and side effects between the two groups of drugs after the treatment of lung adenocarcinoma (P<0.05). The median survival time of patients was 16 months in the icotinib group and 10 months in the pemetrexed group, with a statistically significant difference (P<0.05). The 1‑year survival rate was higher in the icotinib group than that in the pemetrexed group (P<0.05). There was no difference in 2‑ and 3‑year survival rates between the two groups (P>0.05). In conclusion, the clinical efficacy of icotinib is similar to that of pemetrexed in the treatment of lung adenocarcinoma, but icotinib has less adverse reactions, with better improvement in disease control.

Related Articles

Journal Cover

October 2019
Volume 18 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Zhou, X., Hua, D., Gao, C., Zhang, Y., Qiu, L., & Wang, L. (2019). Icotinib and pemetrexed in treatment of lung adenocarcinoma and the effects on prognostic survival rate of patients. Oncology Letters, 18, 4153-4159. https://doi.org/10.3892/ol.2019.10763
MLA
Zhou, X., Hua, D., Gao, C., Zhang, Y., Qiu, L., Wang, L."Icotinib and pemetrexed in treatment of lung adenocarcinoma and the effects on prognostic survival rate of patients". Oncology Letters 18.4 (2019): 4153-4159.
Chicago
Zhou, X., Hua, D., Gao, C., Zhang, Y., Qiu, L., Wang, L."Icotinib and pemetrexed in treatment of lung adenocarcinoma and the effects on prognostic survival rate of patients". Oncology Letters 18, no. 4 (2019): 4153-4159. https://doi.org/10.3892/ol.2019.10763